* Department of Hematology, University Hospital, 3508 GA Utrecht, The Netherlands; Department of Cell Biology, Medical
School, University of Utrecht, 3584 CX Utrecht, The Netherlands; and § Center for Molecular and Cellular Biology, University of
Queensland, St. Lucia, Brisbane 4072, Australia
Increased energy metabolism in the circulating blood platelet plays an essential role in platelet plug
formation and clot retraction. This increased energy
consumption is mainly due to enhanced anaerobic consumption of glucose via the glycolytic pathway. The aim
of the present study was to determine the role of glucose transport as a potential rate-limiting step for human platelet glucose metabolism. We measured in isolated platelet preparations the effect of thrombin and
ADP activation, on glucose transport (2-deoxyglucose
uptake), and the cellular distribution of the platelet glucose transporter (GLUT), GLUT-3. Thrombin (0.5 U/ml) caused a pronounced shape change and secretion
of most -granules within 10 min. During that time glucose transport increased approximately threefold, concomitant with a similar increase in expression of GLUT-3 on the plasma membrane as observed by immunocytochemistry. A major shift in GLUT-3 labeling
was observed from the
-granule membranes in resting
platelets to the plasma membrane after thrombin treatment. ADP induced shape change but no significant
-granule secretion. Accordingly, ADP-treated platelets showed no increased glucose transport and no increased GLUT-3 labeling on the plasma membrane.
These studies suggest that, in human blood platelets, increased energy metabolism may be precisely coupled to
the platelet activation response by means of the translocation of GLUT-3 by regulated secretion of
-granules. Observations in megakaryocytes and platelets
freshly fixed from blood confirmed the predominant GLUT-3 localization in
-granules in the isolated cells,
except that even less GLUT-3 is present at the plasma
membrane in the circulating cells (~15%), indicating
that glucose uptake may be upregulated five to six
times during in vivo activation of platelets.
PLATELETS play a crucial role in hemostasis and
thrombosis. They originate from megakaryocytes in
the bone marrow and adhere to sites of injury. In
their resting state, platelets are nonadhesive, have a discoid shape, and contain a large number of Each of these steps in the functional activation sequence
of the platelet must result in a significant increase in the
energy requirements of this cell. However, there is little
information available regarding the type of fuel used by
the platelet under these conditions, which of these steps is
the most energy costly, or the points of regulation within the
intermediary metabolic pathways that facilitate these
changes. The resting platelet relies predominantly on the
anaerobic metabolism of blood-borne glucose as its major
source of energy (Akkerman, 1978 Skeletal and heart myocytes are other cell types in
which rapid and marked changes in carbohydrate metabolism meet the increased energy demands of actomyosin
contraction, similarly to the platelet. In these cells, the
very first step in the glycolytic breakdown of extracellular
glucose, i.e., glucose entry into the cell, appears to be a
major rate-determining step (Ziel et al., 1988 In view of the possible similarity between platelets and
myocytes in terms of the contraction-induced changes in
carbohydrate metabolism, we have investigated the potential role of glucose transport in platelet activation. We
present evidence that activation of platelets with thrombin
results in a significant increase in 2-deoxyglucose (2-DG)
uptake. Stimulation with ADP, under conditions where
platelet secretion was inhibited, did not cause a significant change in platelet 2-DG uptake. Recently it was reported
that GLUT-3 is the main glucose transporter isoform expressed in platelets (Craik et al., 1995 Antibodies
The anti-human GLUT-3 antibody was raised against a synthetic peptide
corresponding to the last 12 amino acids in the carboxy terminus of the
protein. This antibody has been extensively characterized and is highly
specific for human GLUT-3 (Harris et al., 1992 Platelet Isolation
Blood was taken from healthy donors and was anticoagulated with 0.1 vol
of 0.13 M sodium citrate. Platelet-rich plasma was obtained by centrifugation of whole blood at 180 g for 10 min at 22°C, and then mixed in a 1:1 ratio with Krebs-Ringer buffer, pH 5.0 (4 mM KCl, 100 mM NaCl, 20 mM
NaHCO3, 2 mM Na2SO4, 4.7 mM citric acid, 14.2 tri-sodium citrate). The
platelet pellet was washed twice with the same buffer at pH 6.0. Alternatively, fresh whole blood was collected directly from the vein into fixative containing 2.4% paraformaldehyde and 0.24% glutaraldehyde in 0.1 M sodium phosphate buffer, pH 7.4 (1:5 volume ratio). For biochemical analysis,
samples of the washed platelet suspension were resuspended in Krebs-Ringer buffer, pH 7.4, adjusted to 2 × 109 platelets per ml, and used within 1 h.
Bone Marrow Megakaryocytes
Normal bone marrow samples were obtained after informed consent from
a patient undergoing heart surgery. The megakaryocyte-rich cell suspension was obtained by centrifugation on Ficoll-Paque (Research Grade;
Pharmacia, Uppsala, Sweden). The cells were fixed with a mixture of 2%
paraformaldehyde and 0.2% glutaraldehyde, and then processed for cryosectioning and immunolabeling as described below.
[14C]2-DG Uptake
Aliquots (200 µl) of the washed platelet suspension were diluted in 1.8 ml
0.1 M Hepes- NaCl (0.01 M Hepes, 0.15 M NaCl, pH 7.4) to obtain a final
platelet concentration of 2 × 108/ml. The platelet samples were warmed to
37°C and incubated either in the absence or presence of thrombin. A
dose-dependent stimulation was achieved using concentrations of 0.02, 0.2, and 0.5 U/ml thrombin, respectively. After stimulation for 7 min,
[14C]2-DG was added to the platelet suspension at a final concentration of
10 µM, and the incubation was continued for 3 min. Alternatively, platelets were incubated for 7 min with ADP (10 µM), followed by the addition
of 10 µM [14C]2-DG as described above. In this case the platelets were
preincubated at 37°C for 10 min with 30 µM indomethacin, a specific inhibitor of cyclo-oxygenase, which prevents secretion during ADP stimulation (Kaplan et al., 1979 Cryosectioning and Immunolabeling
Platelet samples were incubated as described for the measurements of
2-DG uptake except that nonradiolabeled 2-DG was used for the incubation. At the conclusion of the 10 min, incubation platelets were immediately fixed using 2% paraformaldehyde and 0.2% glutaraldehyde in 0.1 M
sodium phosphate buffer. Samples were then rinsed three times in 0.1 M
sodium phosphate buffer and embedded in 10% gelatin in PBS at 37°C.
The gelatin was solidified at 4°C, and cut into small blocks. After overnight infiltration in 2.3 M sucrose at 4°C, the cells were frozen in liquid nitrogen. Ultrathin cryosectioning and immunogold labeling were performed as described before (Slot et al., 1991 [14C]2-DG Uptake in Platelets
The measurement of 2-DG uptake provides an estimate of
glucose transport, as this analogue is transported and
phosphorylated like glucose but does not undergo subsequent metabolism. Stimulation with thrombin caused a
rapid increase in 2-DG uptake in human platelets (Fig. 1).
The amount of 2-DG uptake was 1.2-fold when a low dose
of thrombin (0.05 U/ml) was used, while at a dose of 0.5 U/ml a 2.8-fold increase was observed. The specificity of the 2-DG uptake was confirmed by using cytochalasin B, a
specific inhibitor of the facilitative glucose transporter
(Jung and Rampal, 1977
In accordance with a previous study on Western blots of
whole platelet lysates (Craik et al., 1995 Localization of GLUT-3 in Resting Platelets
Ultrathin cryosections of fixed human platelets were immunolabeled with antibodies specific for GLUT-3. In resting platelets, from blood that was collected in fixative, significant immunolabeling of the
Table I.
Intracellular Distribution of GLUT-3 in Blood Platelets
-granules. The
-granules, which are the most abundant granule type in
these cells, contain adhesive proteins such as fibrinogen,
fibronectin, von Willebrand factor (Sixma et al., 1989
;
Sander et al., 1983
), and growth factors such as TGF-
and
PDGF (Linder et al., 1979
). At sites of injury the platelets
become activated, a process that promotes the formation
of a platelet thrombus and wound healing. Platelet activation can be subdivided into several discrete steps. The first
step is the adhesion to exposed components of the subendothelium, which is rapidly followed by a change in cell
shape (Sixma et al., 1987a
,b), due to rearrangement of actin filaments and microtubules, both of which maintain the
discoid nature of the resting platelet (Behnke, 1974
;
Hartwig, 1992
). The next step involves the aggregation of
platelets, which occurs simultaneously with the exocytosis of the
-granules. Finally, the actin filaments associate
with myosin in a process that resembles skeletal muscle
contraction (Cohen et al., 1982
; Fox et al., 1992
). This step
facilitates platelet retraction, which is responsible for clot
contraction.
, 1987
) despite the presence of mitochondria and glycogen particles within these
cells. It is likely that platelet plug formation and clot retraction are also highly dependent on extracellular glucose
as it has been shown that there is a direct relationship between platelet retraction efficiency and glycolytic flux
(Bettex-Galland and Luscher, 1959
). In fact, these and further studies showed that glucose improves platelet retraction efficiency in in vitro assays, suggesting that the consumption of glucose by platelets and the efficiency of clot
retraction must be somehow linked.
). Muscle contraction and other stimuli such as insulin stimulate glucose transport by triggering the movement of a facilitative
glucose transporter (GLUT)1 known as GLUT-4 from an
intracellular compartment to the cell surface (James et al.,
1994
; Cushman and Wardzala, 1980
; Suzuki and Kono,
1980
). Upon cessation of muscle contraction or removal of
the agonist, GLUT-4 is retrieved from the cell surface, and glucose transport and glucose use return to resting levels.
). Accordingly, we
show immunocytochemically that in resting platelets GLUT-3
is localized to the
-granule membrane from where it
moves to the cell surface in response to thrombin. This
regulated translocation of GLUT-3 is responsible for the
increased uptake of 2-DG.
Materials and Methods
). Gold particles, prepared
as described previously (Slot and Geuze, 1985
), were conjugated to protein A (Roth et al., 1978
).
). The [14C]2-DG uptake was arrested by the addition of 10 µM cytochalasin B. The platelet samples were washed three
times with 0.1 M PBS, 50-µl samples were taken, and the total protein
content was measured. The platelet pellet was dissolved in 500 µl 1 N
NaOH and counted in a liquid scintillation counter.
). Sections were picked up
with a drop of a 1:1 mixture of 2.3 M sucrose and 1.8% methyl cellulose
(25 centipoise; Fluka AG, Buchs, Switzerland), thawed, and transferred to
Formvar carbon-coated copper grids (Liou et al., 1996
). The sections were
subsequently immunolabeled at room temperature by floating on drops
containing the diluted antibody. After incubation, the sections were
washed on distilled water, stained for 5 min with uranyl-oxalate, pH 7.0, washed again, and embedded in a mixture of 1.8% methyl cellulose and
0.3% uranyl acetate at 4°C. For quantitative analysis of the GLUT-3 labeling, random electron micrographs were taken at a nominal magnification of 12,000 from directly fixed platelets, nonstimulated washed platelets,
and after stimulation with ADP and thrombin. Gold particles were
counted over
-granules, plasma membrane, including the open canalicular system (OCS), and undefined structures. Gold particle numbers were
expressed as a percentage of the total.
Results
). 2-DG uptake was inhibited by
>90% in the presence of 10 µM cytochalasin B, irrespective of the activation state of the platelets (data not
shown).
Fig. 1.
Glucose transport activity in human platelets. Isolated
platelets were either nonstimulated or stimulated with 10 µM
ADP or 0.05, 0.2, and 0.5 U/ml thrombin, respectively. The
[14C]2-DG uptake was measured as described in Materials and
Methods. The increase in 2- DG uptake upon stimulation is expressed relative to the basal 2-DG values of nonstimulated platelets. The values represent the mean ± SEM of three separate experiments.
[View Larger Version of this Image (11K GIF file)]
), we were unable
to detect any significant expression of GLUT-1, GLUT-2,
or GLUT-4 using isoform-specific antibodies. It is unlikely
that platelets express GLUT-5 because this isoform has a
selective preference for fructose (Burant et al., 1992
), and
previous studies have shown that platelets do not transport fructose (Akkerman, 1978
). Significant labeling was,
however, observed using an antibody specific for human
GLUT-3, confirming that this is probably the major glucose transporter isoform expressed in these cells (Craik et
al., 1995
). We therefore next investigated the intracellular
localization of GLUT-3 in human platelets and their precursor, the megakaryocyte, to further explain the activation-dependent increase in 2-DG uptake.
-granules was observed
(Fig. 2). Most of the immunogold labeling was situated at
the cytoplasmic face of the granules, consistent with the
fact that the antibody was raised against the cytoplasmic
carboxy terminus of GLUT-3 (Harris et al., 1992
). Low labeling of the platelet plasma membrane, including the connected OCS, was also encountered under these conditions.
The relative distribution of GLUT-3 was quantified by
counting the gold particles associated with
-granules, surface membrane, OCS, and undefined structures (Table I).
In resting platelets, 75% of the total gold labeling was associated with the limiting membrane of the
-granules and
15% was detected at the platelet outer surface and the
OCS. The remaining 10% was attributed to structures that were not easily identified. This may represent in part labeling of grazing sections over
-granule membranes and
nonspecific background staining. When megakaryocytes
isolated from bone marrow were immunolabeled with antibodies specific for GLUT-3, we found labeling patterns similar to that in the resting platelets: predominant labeling of the
-granules, and additionally a low expression in
the Golgi complex and demarcating membranes, the precursor of the platelet cell surface (data not shown).
Fig. 2.
Ultrastructural localization of GLUT-3 in human platelets. Frozen thin-sections of resting platelets immediately fixed in whole blood were immunolabeled with an antibody specific for GLUT-3, followed by protein A conjugated to 10 nm gold. The platelets still have their discoid shape. The majority of the label is associated with the limiting membrane of the -granules. Note that the gold particles are often situated at the cytoplasmic face of the membrane, and occasionally in a grazing section with the tip of an
-granule membrane (arrow). Some label is also associated with the plasma membrane (arrowheads). (Stars) OCS. Bar, 200 nm.
[View Larger Version of this Image (126K GIF file)]
Effects of Thrombin and ADP on GLUT-3 Localization
In isolated control platelets that were fixed after 10-min
incubation in Hepes buffer, we found evidence for mild activation. This is a well-established phenomenon and is
hard to avoid during the washing steps of these fragile
cells, in spite of all precautions taken. However, the general morphology of the washed platelets used in our experiments resembled that in resting state fairly well, containing still numerous -granules, and they did not exhibit the
characteristic shape change of an activated platelet. Under these conditions, 67% of the total immunogold labeling
was associated with the
-granules and 23% was found on
OCS and surface membranes (Table I). In response to 0.05 U/ml of thrombin, the platelets underwent the shape
changes characteristic for a low stimulatory response (i.e.,
centralization of
-granules and the beginning of cell surface ruffling). No substantial redistribution of GLUT-3 was observed under these conditions. Incubation with 0.2 and 0.5 U/ml thrombin caused a marked activation of the
platelets, concomitant with a substantial redistribution of
GLUT-3 to the platelet cell surface membranes. A majority of the
-granules had fused with membranes of the cell
surface and the OCS, leaving large vacuoles with released
contents in the center (Fig. 3, a and b). A dose of 0.05, 0.2, or 0.5 U/ml thrombin caused a 1.4-, 2.8-, or 3.3-fold increase in GLUT-3 labeling at the plasma membrane, concomitant with a 1.3-, 1.9-, or 2.8-fold increase in 2-DG uptake, when compared with controls.
To determine if the changes in 2-DG uptake were triggered by changes in cell shape or activation of the platelet
contractile apparatus, the effect of ADP on GLUT-3 localization was measured. In agreement with previous findings, ADP caused characteristic changes in platelet shape,
i.e., centralization of -granules and the formation of
pseudopodal extensions (Fig. 4). Under the experimental
conditions, ADP had no effect on the number of intracellular
-granules, as well as on the distribution of GLUT-3
in platelets (Fig. 4; Table I), which is consistent with the inability of ADP to trigger a change in 2-DG uptake (Fig. 1).
In the present study we show that activation of human
platelets with thrombin causes a rapid stimulation of glucose uptake, suggesting that this may be a key metabolic
step for the generation of ATP to sustain the increased energy demands during thrombus formation. This acute elevation in transport is precisely coupled to platelet activation via the efficient targeting of the major facilitative
transporter found in this cell, GLUT-3, from the intracellular -granules toward the cell surface. As these granules fuse with the cell surface, there is a significant increase in surface levels of GLUT-3, accompanied by an increased
glucose transport activity, which was of similar magnitude
at the different levels of activation (Fig. 1 vs Table I) We
could not measure glucose uptake in circulating human
blood platelets, but our immunocytochemical data indicate that, compared with the very low levels (~15%) in resting, directly fixed platelets, a five- to sixfold increase in
GLUT-3 surface expression occurs during full platelet activation. The parallel course of increases in GLUT-3 surface expression and glucose uptake that we measured in
isolated platelet preparations suggests that glucose transport likewise can be upregulated five- to sixfold when circulating platelets are activated in vivo.
Previous studies have shown that extracellular glucose is
an important source of energy for human platelets (Akkerman, 1978, 1987
). Moreover, much of the metabolic
flux in platelets appears to be directed toward lactate production. In view of the relatively low energy yield of this
pathway (~2 mol ATP per mol glucose), compared with
the TCA cycle (~36 mol ATP per mol glucose), it is likely
that the flux through this pathway must increase substantially during platelet activation when the ATP requirements to maintain contraction of the actomyosin system as
well as other functions are likely to be quite significant.
However, the rate-determining steps in the glycolytic
pathway that facilitate these changes in platelet metabolism have not been defined. The free intracellular glucose
concentration is very low in platelets, suggesting that the
rate of flux through this step is not in equilibrium with other steps in the glycolytic pathway (Akkerman, 1978
,
1987
). This provided a clue that the glucose transport step
could play an important role as a rate-determining step in
this cell. Until recently, however, very little was known
concerning the platelet glucose transport system.
Over the past decade a family of facilitative glucose
transporters have been identified in mammals (Mueckler,
1994). Each member of this family, referred to as GLUTs
1-7, displays a unique tissue distribution, as well as characteristic kinetic properties that appear to enable different
cell types to respond appropriately to a particular metabolic situation. For example, GLUT-2, which is found in
liver and pancreatic B cells, has a very low affinity for glucose (Colville et al., 1993
). This is probably advantageous for these particular cells, enabling them to transmit
changes in the circulation to the cell interior. Using antibodies specific for each glucose transporter isoform, it was
recently reported that platelets predominantly express
GLUT-3 (Craik et al., 1995
), which was confirmed by the
present immunolocalization study. GLUT-3 has a particularly low Km for glucose, allowing it to transport efficiently
even when blood glucose levels are very low (Gould et al.,
1991
). Since the internal environment of a platelet plug is
deprived of blood flow, this may explain the selective advantage of using the GLUT-3 isotype. The irreversible surface expression of GLUT-3 may be a desirable feature to
ensure that, after the secretory process is complete, high
cell surface levels of GLUT-3 are maintained. It enables
the platelets to maintain prolonged access to extracellular
glucose throughout the course of hemostatic plug formation, thereby providing a continuous source of energy for
platelet contraction.
The major tissues in which GLUT-3 expression has been
reported are brain (Kayano et al., 1988), mouse embryos
(Pantaleon et al., 1997
), sperm (Burant and Davidson,
1994
), and polarized epithelial cells derived from human
tumors (Harris et al., 1992
). The subcellular distribution of
GLUT-3 in each of these tissues differs from that of other
transporters, thus providing an unique feature of this isoform. In mouse embryos, MDCK cells (Pascoe et al.,
1996
), and CaCo2 cells (Harris et al., 1992
), GLUT-3 is
targeted to the apical cell surface. In neurons, GLUT-3 appears to be targeted to axons (James, D.E., unpublished
data), whereas in sperm it is found predominantly in the
tail (Slot, J.W., and D.E. James, unpublished observations). Hence, it will be of interest to determine if similar motifs are responsible for maintaining each of these
unique targeting phenotypes, and if there is some link between each of these targeting events and the localization of
GLUT-3 to the limiting membrane of the
-granules in
platelets. A targeting motif that regulates the sequestration of P-selectin in secretory granules has been identified
(Koedam et al., 1992
), but we have been unable to identify a motif resembling this in GLUT-3.
In all cell types studied, GLUT-3 molecules are almost
exclusively confined to the plasma membrane (Pascoe et
al., 1996; Harris et al., 1992
), in agreement with the absence of a consensus internalization signal in the cytosolic
domains of GLUT-3 (Asano et al., 1992
). In contrast,
platelets harbor most of their GLUT-3 intracellularly in
-granule membranes. These are most likely biosynthetic
GLUT-3 molecules that are stored in the
-granules before
their translocation to the cell surface by stimulated
-granule release. This is an irreversible process and occurs only
once in the platelet's life time, during activation. The only
glucose transporter normally stored intracellularly in resting cells is GLUT-4, which resides in an endosome-related
compartment until it becomes transiently expressed at the
cell surface after stimulation (James et al., 1994
). Interestingly, we have recently observed a major pool of intracellular GLUT-4 molecules residing in the membranes of
regulated secretory granules in atrial myocytes (Slot et al.,
1997
). Several lines of evidence indicated that these GLUT-4
molecules derive from endocytosis rather than from the
biosynthetic pathway. Thus, while atrial myocytes seem to
exploit secretion of their storage granules to ensure stimulus-dependent repetitive endocytotic and translocation cycles of GLUT-4, platelets store biosynthetic GLUT-3 in
-granules during differentiation from megakaryocytes
until the platelets are stimulated to release the
-granules
before disintegration during clot formation.
Received for publication 17 February 1997 and in revised form 15 May 1997.
Please address all correspondence to Harry F.G. Heijnen, Department of Hematology, University Hospital, P.O. Box 85500, 3508 GA Utrecht, The Netherlands. Tel.: (31) 30-2507769. Fax: (31) 30-2511893. e-mail: H.F.G.Heijnen{at}lab.azu.nl2-DG, 2-deoxyglucose; GLUT, glucose transporter; OCS, open canalicular system.
1. | Akkerman, J.W.N.. 1978. Regulation of carbohydrate metabolism in platelets. A Review. Thromb. Haemostasis. 39: 712-724 |
2. | Akkerman, J.W.N. 1987. Carbohydrate metabolism. In Platelet Responses and Metabolism. H. Holmsen, editor. CRC Press, Inc., Boca Raton, FL. 189-213. |
3. | Asano, T., H. Katagiri, K. Taakata, K. Tsukuda, J.L. Lin, H. Ishihara, K. Inukai, H. Hirano, Y. Yazaki, and Y. Oka. 1992. Characterization of GLUT3 protein expressed in Chinese hamster ovary cells. Biochem. J. 288: 189-193 |
4. | Behnke, O.. 1974. Microtubules and microfilaments. Triangle. 13: 7-15 |
5. | Bettex-Galland, M., and E.F. Luscher. 1959. Extraction of an actomyosin-like protein from human thrombocytes. Nature (Lond.). 184: 276-277 |
6. |
Burant, C.F., and
N.O. Davidson.
1994.
GLUT3 glucose transporter isoform in
rat testis: localization, effect of diabetes mellites, and comparison to human
testis.
Am. J. Physiol.
267:
R1488-R1495
|
7. |
Burant, C.F.,
J. Takeda,
L.E. Brot-Laroche,
G.I. Bell, and
N.O. Davidson.
1992.
Fructose transporter in human spermatozoa and small intestine is GLUT5.
J.
Biol. Chem.
267:
14523-14526
|
8. | Cohen, I., J.M. Gerrard, and J.G. White. 1982. Ultrastructure of clots during isometric contraction. J. Cell Biol. 93: 775-787 [Abstract]. |
9. | Colville, C.A., M.J. Seatter, T.J. Jess, G.W. Gould, and H.M. Thomas. 1993. Kinetic analysis of the liver-type (GLUT2) and brain-type (GLUT3) glucose transporters in Xenopus oocytes: substrate specifities and effects of transport inhibitors. Biochem. J. 290: 701-706 |
10. | Craik, J.D., M. Stewart, and C.I. Cheeseman. 1995. GLUT-3 (brain-type) glucose transporter polypeptides in human blood platelets. Thromb. Res. 79: 461-469 |
11. |
Cushman, S.W., and
L.J. Wardzala.
1980.
Potential mechanism of insulin action
on glucose transport in the isolated rat adipose cell. Apparent translocation
of intracellular transport systems to the plasma membrane.
J. Biol. Chem.
255:
4758-4762
|
12. | Fox, J.E., C.C. Reynolds, and J.K. Boyles. 1992. Studying the platelet cytoskeleton in Triton X-100 lysates. Methods Enzymol. 215: 42-58 |
13. | Gould, G.W., H.M. Thomas, T.J. Jess, and G.I. Bell. 1991. Expression of human glucose transporters in Xenopus oocytes: kinetic characterization and substrate specificities of the erythrocyte, liver, and brain isoforms. Biochemistry. 30: 5139-5145 |
14. | Harris, D.S., J.W. Slot, H.J. Geuze, and D.E. James. 1992. Polarized distribution of glucose transporter isoforms in Caco-2 cells. Proc. Natl. Acad. Sci. USA. 89: 7556-7560 [Abstract]. |
15. | Hartwig, J.H.. 1992. Mechanisms of actin rearrangements mediating platelet activation. J. Cell Biol. 118: 1421-1442 [Abstract]. |
16. | James, D.E., R.C. Piper, and J.W. Slot. 1994. Insulin stimulation of GLUT-4 translocation: a model for regulated recycling. Trends Cell Biol. 4: 120-126 . |
17. | Jung, C.Y., and A.L. Rampal. 1977. Cytochalasin B binding sites and glucose transport carrier in human erythrocyte ghosts. J. Biol. Chem. 252: 5456-5463 |
18. | Kaplan, K.L., M.J. Broekman, A. Chernoff, G.R. Lesznik, and M. Drillings. 1979. Platelet alpha-granule proteins: studies on release and subcellular localization. Blood. 53: 604-618 |
19. |
Kayano, T.,
H. Fukumoto,
R.L. Eddy,
F.-S. Fan,
M.G. Byers,
T.B. Shows, and
G.I. Bell.
1988.
Evidence for a family of human glucose transporter-like proteins.
J. Biol. Chem.
263:
15245-15248
|
20. | Koedam, J.A., E.M. Cramer, E. Briend, B. Furie, B.C. Furie, and D.D. Wagner. 1992. P-selectin, a granule membrane protein of platelets and endothelial cells, follows the regulated secretory pathway in AtT-20 cells. J. Cell Biol. 116: 617-625 [Abstract]. |
21. | Linder, B.L., A. Chernoff, K.L. Kaplan, and D.S. Goodman. 1979. Release of platelet-derived growth factor from human platelets by arachidonic acid. Proc. Natl. Acad. Sci. USA. 76: 4107-4111 [Abstract]. |
22. | Liou, W., H.J. Geuze, and J.W. Slot. 1996. Improving structural integrity of cryosections for immunogold labeling. Histochem. Cell Biol. 106: 41-58 |
23. | Mueckler, M.. 1994. Facilitative glucose transporters. Eur. J. Biochem. 219: 713-725 [Abstract]. |
24. |
Pantaleon, M.,
M.B. Harvey,
W.S. Pascoe,
D.E. James, and
P.L. Kaye.
1997.
GLUT3: ontogeny, targeting and role in the mouse blastocyst.
Proc. Natl.
Acad. Sci. USA.
94:
3795-3800
|
25. |
Pascoe, W.S.,
K. Inukai,
Y. Oka,
J.W. Slot, and
D.E. James.
1996.
Differential
targeting of facilitative glucose transporters in polarized epithelial cells.
Am.
J. Physiol.
271:
C547-C554
|
26. | Roth, J., M. Bendayan, and L. Orci. 1978. Ultrastructural localization of intracellular antigens by the use of protein-A gold complex. J. Histochem. Cytochem. 26: 1074-1081 [Abstract]. |
27. | Sander, H.J., J.W. Slot, B.N. Bouma, P.A. Bolhuis, D.S. Pepper, and J.J. Sixma. 1983. Immunocytochemical localization of fibrinogen, platelet factor 4, and beta-thromboglobulin in thin frozen sections of human blood platelets. J. Clin. Invest. 72: 1277-1287 |
28. | Sixma, J.J., P.F. Nievelstein, W.P. Houdijk, H. Van Breugel, and G. Hindriks. 1987a. Adhesion of blood platelets to isolated components of the vessel wall. Ann. NY Acad. Sci. 509: 103-117 |
29. | Sixma, J.J., P.F. Nievelstein, J.J. Zwaginga, and P.G. de Groot. 1987b. Adhesion of blood platelets to the extracellular matrix of cultured human endothelial cells. Ann. NY Acad. Sci. 516: 39-51 |
30. | Sixma, J.J., J.W. Slot, and H.J. Geuze. 1989. Immunocytochemical localization of platelet granule proteins. Methods Enzymol. 169: 301-311 |
31. | Slot, J.W., and H.J. Geuze. 1985. A new method of preparing gold probes for multiple-labeling cytochemistry. Eur. J. Cell Biol. 38: 87-93 |
32. | Slot, J.W., H.J. Geuze, S. Gigengack, G.E. Lienhard, and D.E. James. 1991. Immunolocalization of the insulin regulatable glucose transporter in brown adipose tissue of the rat. J. Cell Biol. 113: 123-135 [Abstract]. |
33. |
Slot, J.W.,
G. Garruti,
S. Martin,
V. Oorschot,
G. Posthuma,
E.W. Kraegen,
R. Laybutt,
G. Thibault, and
D.E. James.
1997.
Glucose transporter (GLUT-4)
is targeted to secretory granules in rat atrial cardiomyocytes.
J. Cell Biol.
137:
1243-1254
|
34. | Suzuki, I., and T. Kono. 1980. Evidence that insulin causes translocation of glucose transport activity to the plasma membrane from an intracellular storage site. Proc. Natl. Acad. Sci. USA. 77: 2542-2545 [Abstract]. |
35. | Ziel, F.H., N. Venkatesan, and M.B. Davidson. 1988. Glucose transport is rate limiting for skeletal muscle glucose metabolism in normal and STZ-induced diabetic rats. Diabetes. 37: 885-890 [Abstract]. |